Bosch finds buyers for its packaging machinery business

16 Jul 2019

CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".

Bosch plans to sell its packaging machinery business, based in Waiblingen, to a newly incorporated entity managed by CVC Capital Partners (CVC). The company and its Pharma and Food units will remain intact. Based in Luxemburg, CVC is a leading private equity and investment advisory firm with 24 offices in Europe, Asia, and the US. It currently manages more than US$75 billion of assets.

Bosch finds buyers for its packaging machinery business

The parties signed an agreement on 11 July 2019 effecting the transfer of the entire packaging technology business and its 6,100 associates in 15 countries. It has been agreed that the purchase price and other details of the purchase agreement will not be disclosed. Completion of the sale is subject to the approval of various bodies, including antitrust authorities, and is expected to close at the turn of the year.

Positive prospects for the Packaging Technology business

Dr Alexander Dibelius, Managing Partner of CVC, said: “Bosch Packaging Technology is a strong company in an attractive market with long-term growth prospects. Packaging Technology has an excellent reputation for quality and innovation, a broad product range, a global footprint, and experienced associates. Together with the management team, we will work to take the business forward in the years ahead, and to make it even more competitive.”

Dr Stefan König, the President of Robert Bosch Packaging Technology, said: “My colleagues and I in executive management regard this new partnership with CVC as a huge opportunity for our future success. Just under 2 years ago, we completely modified our strategy. It now includes working on a completely new range of smart and sustainable process and packaging technologies. This will allow us to offer our customers even more attractive product solutions and services in the future. Our customers and our associates will benefit from the progress we have made.”

Dr Stefan Hartung, member of the board of management of Robert Bosch and chairman of the supervisory board Robert Bosch Packaging Technology, said: “With its experience in growing companies over the long term, its broad industrial expertise, and its viable strategy for taking the division forward, CVC was the right choice for us. The growth concept it has presented, as well as the investments it plans to make, are very promising. For Packaging Technology and all its associates, our aim was to find a reliable new owner with a long-term approach, under whose leadership the business can develop successfully. We have achieved just that.”

Bosch is consolidating its resources

Bosch announced a year ago that it was looking for a buyer for its packaging technology business. The company is giving increasing attention to mobility and connectivity over the internet of things. It is focusing its existing resources on areas of future importance, such as shaping the transformation process and preparing for further digitalization. Bosch firmly believes that the Packaging Technology division’s competitiveness, and thus also its future viability, can be further enhanced through this new partnership, and that significant stimuli for growth can be created.

Read More

Related news

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

10 Sep 2019

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Catalent to open new clinical supply facility in San Diego

Catalent to open new clinical supply facility in San Diego

6 Sep 2019

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more 
Velesco Pharma to triple its clinical manufacturing capacity

Velesco Pharma to triple its clinical manufacturing capacity

4 Sep 2019

Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.

Read more 
Taiwan's biggest CDMO secures FDA approval

Taiwan's biggest CDMO secures FDA approval

3 Sep 2019

Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.

Read more 
China relaxes import regulations to improve access and availability of affordable medicines

China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

Read more 
Dutch company receives €20 million for skin cancer diagnostic test

Dutch company receives €20 million for skin cancer diagnostic test

3 Sep 2019

The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.

Read more